Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy
- PMID: 30442055
- DOI: 10.1080/13816810.2018.1536219
Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy
Abstract
Background: Central serous chorioretinopathy (CSC) is a common chorioretinal disease, characterized by choroidal hyperpermeability leading to neurosensory and/or retinal pigment epithelial detachments. Hypofibrinolysis due to higher plasma concentrations of plasminogen activator type 1 (PAI-1) or lower activity of tissue-type plasminogen activator (t-PA) has been implicated in the pathogenesis of CSC. Functional polymorphisms in the PAI-1 (SERPINE1) and t-Pa (PLAT) are thus potential risk factors for CSC. The aim of the present study was therefore to investigate a hypothesized association between the PAI-1 4G/5G and the t-PA -7351C > T gene variants and the presence of CSC.
Methods: The present study comprised 172 CSC patients and 313 control subjects. Genotypes of the PAI-1 4G/5G and the t-PA -7351C > T polymorphisms were determined by TaqManTM fluorogenic 5'-exonuclease assays.
Results: Allelic frequencies or genotype distributions of neither the PAI-1 4G/5G nor the t-PA -7531C > T polymorphisms were significantly different between patients with CSC and control subjects (PAI-1 4G/4G: 24.4% vs. 20.4, p = 0.36; t-PA -7351CC: 42.4% vs. 46.0%, p = 0.50). After adjusting for age and gender presence of the PAI-1 4G/4G genotype was associated with a non-significant odds ratio (OR) of 1.21 (95% confidence interval [95% CI]: 0.77-1.92, p = 0.41), while homozygosity for the t-PA -7351C allele yielded a non-significant OR of 0.91 (95% CI: 0.62-1.33, p = 0.62) for CSC.
Conclusion: The present study suggests that both the t-PA -7351C > T and the PAI-1 4G/5G gene variants are unlikely major risk factors for CSC.
Keywords: Central serous chorioretinopathy; genetic polymorphism; plasminogen activator type 1; risk factor; tissue-type plasminogen activator.
Similar articles
-
Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis.J Periodontol. 2007 Jul;78(7):1256-63. doi: 10.1902/jop.2007.060383. J Periodontol. 2007. PMID: 17608581
-
The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels.Cutan Ocul Toxicol. 2014 Dec;33(4):270-4. doi: 10.3109/15569527.2013.854372. Epub 2014 Jan 22. Cutan Ocul Toxicol. 2014. PMID: 24446892
-
Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.J Korean Med Sci. 2003 Feb;18(1):58-64. doi: 10.3346/jkms.2003.18.1.58. J Korean Med Sci. 2003. PMID: 12589088 Free PMC article.
-
Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis.Eur J Obstet Gynecol Reprod Biol. 2014 Apr;175:8-14. doi: 10.1016/j.ejogrb.2013.12.030. Epub 2014 Jan 3. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24439532 Review.
-
Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility.Clin Exp Allergy. 2006 Jul;36(7):872-6. doi: 10.1111/j.1365-2222.2006.02413.x. Clin Exp Allergy. 2006. PMID: 16839401 Review.
Cited by
-
The Genetic Background of Central Serous Chorioretinopathy: A Review on Central Serous Chorioretinopathy Genes.J Genomics. 2021 Jan 1;9:10-19. doi: 10.7150/jgen.55545. eCollection 2021. J Genomics. 2021. PMID: 33456587 Free PMC article. Review.
-
Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy.Sci Rep. 2020 Nov 19;10(1):20175. doi: 10.1038/s41598-020-77202-y. Sci Rep. 2020. PMID: 33214636 Free PMC article.
-
Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review.Pharmaceuticals (Basel). 2020 Sep 23;13(10):264. doi: 10.3390/ph13100264. Pharmaceuticals (Basel). 2020. PMID: 32977380 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous